Physician

Tomasz Stryjewski, MD

According to 2025 Medicare claims, Tomasz Stryjewski, MD (NPI: 1164860151) practices ophthalmology in the Cambridge-Newton-Framingham, MA market, with the plurality of this provider's patient population coming from Essex, MA. This provider's primary affiliated billing organization is TALLMAN EYE ASSOCIATES, PC (NPI: 1194833467; TIN: 04-2624483) and primary practice location at 01843-1764. Stryjewski is affiliated with the Lahey Clinical Performance ACO (ACO ID: A1490), participating under the MSSP model.

Stryjewski's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 729 traditional Medicare patients, billed 17,345 HCPCS/CPT codes, and received $1,193,672 in Medicare payments. The top billing code was J0178 (Injection, aflibercept, 1 mg). Part D data shows 609 prescription claims across 194 beneficiaries totaling $31,499 in drug costs, led by Prednisolone Acetate (Prednisolone Acetate). Open Payments data shows 6 records totaling $263. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $19,838 to $1,193,672. Similarly, Part D prescription costs have risen steadily, from $5,248 to $31,499. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$597K$1.2M2017 Medicare payment: $19,838 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $29,485 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $34,434 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $152,579 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $705,587 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $835,271 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $1,000,450 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $1,193,672 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
20174687$19,838
2018249343$29,485
2019437574$34,434
2020222709$152,579
20215703,938$705,587
20226854,797$835,271
20237378,258$1,000,450
202472917,345$1,193,672

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$16K$31K2015 Drug cost: $5,248 (USD; Tot_Drug_Cst)2016 Drug cost: $6,086 (USD; Tot_Drug_Cst)2017 Drug cost: $14,553 (USD; Tot_Drug_Cst)2018 Drug cost: $11,049 (USD; Tot_Drug_Cst)2019 Drug cost: $22,223 (USD; Tot_Drug_Cst)2020 Drug cost: $10,100 (USD; Tot_Drug_Cst)2021 Drug cost: $18,474 (USD; Tot_Drug_Cst)2022 Drug cost: $22,190 (USD; Tot_Drug_Cst)2023 Drug cost: $29,184 (USD; Tot_Drug_Cst)2024 Drug cost: $31,499 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
201550111$5,248
201650135$6,086
201789271$14,553
201893249$11,049
2019160480$22,223
202078227$10,100
2021121493$18,474
2022126431$22,190
2023158526$29,184
2024194609$31,499

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
J0178Injection, aflibercept, 1 mg112704$659
92014Established patient complete exam of visual system624824$90
67028Injection of drug into eye190709$84
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more116241$67
92134Imaging of retina6561,282$31

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Prednisolone AcetatePrednisolone Acetate1747,666$9,331
Ketorolac TromethamineKetorolac Tromethamine1274,987$3,641
OfloxacinOfloxacin1184,336$1,976
Tobramycin-DexamethasoneTobramycin/Dexamethasone14390$958
LatanoprostLatanoprost543,476$706

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.6$263Carl Zeiss Meditec, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Tomasz Stryjewski, MD?

Tedicare shows public-source Medicare data for Tomasz Stryjewski, MD (NPI 1164860151), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Tomasz Stryjewski, MD have ACO affiliation data?

Tomasz Stryjewski, MD is shown with ACO affiliation data for Lahey Clinical Performance ACO (MSSP, ACO ID A1490).

What billing organization is linked to Tomasz Stryjewski, MD?

Tomasz Stryjewski, MD is linked to TALLMAN EYE ASSOCIATES, PC (billing NPI 1194833467) in the available physician profile data.

Does Tomasz Stryjewski, MD have Open Payments data?

Tomasz Stryjewski, MD has 6 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.